Vimian Group AB (publ) (VIMGF)
USD 3.62
(0.0%)
USD 3.62
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 9.84 Million EUR | 243.69% |
| 2022 | -6.84 Million USD | -203.98% |
| 2021 | 6.58 Million USD | -87.53% |
| 2020 | 52.79 Million USD | 3819.0% |
| 2019 | -1.41 Million USD | -55.21% |
| 2018 | -914.64 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -2.12 Million USD | -143.65% |
| 2024 Q2 | 4.87 Million USD | 39.09% |
| 2024 Q1 | 3.5 Million EUR | 158.45% |
| 2023 FY | 9.84 Million USD | 243.69% |
| 2023 Q2 | 2.99 Million USD | -44.62% |
| 2023 Q1 | 5.4 Million USD | 125.19% |
| 2023 Q3 | 7.43 Million USD | 148.23% |
| 2023 Q4 | -7.31 Million USD | -198.39% |
| 2022 Q3 | -1.54 Million USD | -115.43% |
| 2022 FY | -6.84 Million USD | -203.98% |
| 2022 Q4 | -21.45 Million USD | -1292.05% |
| 2022 Q2 | 9.99 Million EUR | 84.22% |
| 2022 Q1 | 5.42 Million EUR | 167.98% |
| 2021 FY | 6.58 Million USD | -87.53% |
| 2021 Q3 | -318.99 Thousand EUR | 91.25% |
| 2021 Q4 | 2.02 Million EUR | 734.5% |
| 2021 Q2 | -3.64 Million EUR | -146.09% |
| 2021 Q1 | 7.91 Million EUR | -85.24% |
| 2020 Q4 | 53.6 Million EUR | 22906.01% |
| 2020 FY | 52.79 Million USD | 3819.0% |
| 2020 Q2 | -971 Thousand EUR | -267.7% |
| 2020 Q1 | 579 Thousand EUR | 0.0% |
| 2020 Q3 | 233 Thousand EUR | 124.0% |
| 2019 FY | -1.41 Million USD | -55.21% |
| 2018 FY | -914.64 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | 797.872% |
| Arrayit Corporation | -3.31 Million USD | 396.779% |
| Atlantic International Corp. | -5.62 Million USD | 274.853% |
| Biocept, Inc. | -32.08 Million USD | 130.667% |
| Bioqual, Inc. | 483.48 Thousand USD | -1935.24% |
| CardioGenics Holdings Inc | -1.91 Million USD | 613.483% |
| DermTech, Inc. | -100.88 Million USD | 109.753% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 99.514% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 145.567% |
| iMD Companies, Inc. | -200.63 Thousand USD | 5004.404% |
| IDenta Corp. | 14.64 Thousand USD | -67094.756% |
| Interpace Biosciences, Inc. | 802 Thousand USD | -1126.933% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | -25333.586% |
| InVitro International | 1553.00 USD | -633512.363% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 214.525% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 17032.819% |
| Medical Imaging Corp. | -3.02 Million USD | 425.502% |
| NovelStem International Corp. | -4.18 Million USD | 334.996% |
| Optigenex Inc. | -2.89 Million USD | 439.573% |
| PharmChem, Inc. | 845.1 Thousand USD | -1064.356% |
| Proteome Sciences plc | -2.44 Million USD | 502.783% |
| Response Genetics, Inc | -20.18 Million USD | 148.751% |
| Rennova Health, Inc. | -3.29 Million USD | 398.811% |
| RushNet, Inc. | -607.02 Thousand USD | 1721.013% |
| ScreenPro Security Inc. | -2.24 Million USD | 537.573% |
| Stella Diagnostics Inc. | -5.7 Million USD | 272.407% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 186.2% |
| Todos Medical Ltd. | -24.99 Million USD | 139.369% |